Majority of female cancer survivors at low risk of developing most obstetric complications

 

  • Low risk of pregnancy complications for most cancer survivors
  • Survivors of cervical cancer and leukaemia are at risk of several serious obstetric complications; authors argue for consultant care in pregnancy as standard
  • Study of 100,000 women finds significantly fewer births among cancer survivors

In a paper published in The Lancet Oncology today led by a research team at the University of Birmingham analysed data from almost 100,000 female survivors of cancer who had been diagnosed aged 15-39, between 1971 and 2006.

From that cohort, between 1997-2022 there had been 21,437 births recorded among 13,886 women who had survived a cancer, which was 32% lower than in the general population. Survivors of some cancers saw less than half the expected numbers of births, including breast and cervical cancers.

The data show that most expectant mothers saw a low likelihood of developing a complication in pregnancy or during birth, although there was a greater risk for leukaemia and cervical cancer survivors who were at increased risk of multiple complications, other specific cancers generally carried a low risk of complications.

To ensure that cancer survivors looking to start a family receive support and assurance about managing any risks, the researchers recommend that formal guidelines are introduced including ensuring that cancer survivors who are at risk of complications receive consultant-led antenatal care.

Dr Raoul Reulen from the Institute of Applied Public Health at the University of Birmingham and lead senior author of the paper said:

In the largest observational study of its kind, we can see that women who survived a cancer are still less likely to give birth than women in the general population. Women may experience increased worry about the risk of complications during pregnancy and delivery following a cancer diagnosis.

Our findings suggest that cancer survivors who didn’t have cervical cancer or leukaemia can feel reassured about their risks going into pregnancy as they do not greatly differ from the risks in the general public for the majority of obstetric complications. However, depending on their previous cancer type, some survivors were at a higher risk for one or two types of complications, for example our study found survivors of kidney cancer had an increased risk of gestational hypertension.

Only survivors of cervical cancer and leukaemia had an increased risk for more than two specific complications from among the 27 complications investigated. We hope these findings can provide evidence for the development of clinical guidelines relating to counselling and surveillance of obstetrical risk for female cancer survivors.

Case study: Diagnosed with cancer while 29 weeks pregnant

Nancy (not her real name) was in her 30s was 29 weeks pregnant with her second child when she was diagnosed with Multiple Myeloma in 2012. Her main complaint during routine ante-natal appointments was fatigue and blood tests showed extremely low iron levels. Further investigation and intervention including iron infusions and a bone marrow biopsy which confirmed the diagnosis.

After giving birth, Nancy had eight rounds of chemotherapy followed by an Autograft transplant in 2013. In 2015 she relapsed and following seven rounds of chemotherapy, a further Autograft and an Allograft transplant, has since been in remission.

Nancy who is a member of Anthony Nolan’s Policy Insights Panel, explained: “Being pregnant, my age and gender meant I was somewhat of an anomaly. I was outside of the normal range and cohort of patients affected by this disease and initially felt isolated, when looking for information to support me and my family’s rare situation. My Clinical Nurse Specialist (CNS) and Consultant were and continue to be empathetic to my needs as cancer patient and from the outset understood the necessity of having access to emotional well-being support alongside the medical intervention.

I found the findings of this study interesting and informative, particularly the impact of chemotherapy and conditioning treatment for girls and women who were diagnosed with a blood cancer. I think research focusing the complexities of cancer treatment for females of childbearing age with specific cancers is important to understand, at every stage of the female cancer journey. 

The long-term effects are life altering and treatment options for cancer patients are as diverse as the patients themselves. The specificity of this study makes it useful and beneficial to my personal experience. Moreover, it gives me confidence in the future of further studies and understanding of pregnant mothers with cancer, pre and post treatment.

Ceren Sunguc, PhD researcher at the University of Birmingham and first author of the study said:

Our data shows that there are some specific cancers in female survivors that are having the biggest impact on births. Cervical cancer, leukaemia, breast and cancers of the genitourinary area not including the bladder, kidney, cervix or ovary had among the lowest birth rates.

Our findings give a much richer picture of how women who have survived cancer may be at risk of developing complications during pregnancy and birth, and we hope that the findings will enable better, more personalised care for women when they are expecting.

The study was funded by Children with Cancer UK, The Brain Tumour Charity and the Academy of Medical Sciences’

ENDS

For media enquiries please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7815 607 157.

Notes to editor:

  • The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries.
  • The University of Birmingham is a founding member of Birmingham Health Partners (BHP), a strategic alliance which transcends organisational boundaries to rapidly translate healthcare research findings into new diagnostics, drugs and devices for patients. Birmingham Health Partners is a strategic alliance between seven organisations who collaborate to bring healthcare innovations through to clinical application:
    • University of Birmingham
    • University Hospitals Birmingham NHS Foundation Trust
    • Birmingham Women’s and Children’s Hospitals NHS Foundation Trust
    • Aston University
    • The Royal Orthopaedic Hospital NHS Foundation Trust
    • Sandwell and West Birmingham Hospitals NHS Trust
    • West Midlands Academic Health Science Network
    • Birmingham and Solihull Mental Health NHS Foundation Trust

Relevant publications include International Late Effects of Childhood Cancer Guideline Harmonization Group pancare guidance published in AJOG 2020: https://www.ajog.org/article/S0002-9378(20)30614-1/fulltext

Royal College of Obstetrics and Gynaecology have published green top guidelines on pregnancy following breast cancer: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/pregnancy-and-breast-cancer-green-top-guideline-no-12/

ENDS 

For media enquiries please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7815 607157: email: t.mayo@bham.ac.uk  

Notes to editor: 

  • The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries. 
  • The University of Birmingham is a founding member of Birmingham Health Partners (BHP), a strategic alliance which transcends organisational boundaries to rapidly translate healthcare research findings into new diagnostics, drugs and devices for patients. Birmingham Health Partners is a strategic alliance between seven organisations who collaborate to bring healthcare innovations through to clinical application:
  • University of Birmingham
  • University Hospitals Birmingham NHS Foundation Trust
  • Birmingham Women’s and Children’s Hospitals NHS Foundation Trust
  • Aston University
  • The Royal Orthopaedic Hospital NHS Foundation Trust 
  • Sandwell and West Birmingham Hospitals NHS Trust
  • West Midlands Academic Health Science Network
  • Birmingham and Solihull Mental Health NHS Foundation Trust


About Children with Cancer UK
 

Children with Cancer UK is a leading children’s cancer charity dedicated to raising and investing funds into vital specialist research to save the lives of children and young people with cancer. Our mission is to improve survival rates and the quality of survival in young patients, and to find ways to prevent cancer in the future. Whilst working towards this, Children with Cancer UK funds support for children and their families as they navigate treatment. What began as a small memorial charity in 1988, has evolved into a major force raising more than £300 million and investing in over 200 pioneering research projects.

For more information about Children with Cancer UK, visit www.childrenwithcancer.org.uk 


About Cancer Research UK for Children & Young People:
 

  • Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information.  
  • Cancer Research UK is the largest charitable funder of research into cancers that affect children and young people in the UK.  
  • Cancer Research UK for Children & Young People is the part of Cancer Research UK dedicated to supporting research into cancers affecting 0-24-year-olds.   
  • Around 32,600 cancer deaths in children and young people have been avoided since the 1970s in the UK, thanks in part to the work of Cancer Research UK.*  
  • Together with its partners and supporters, Cancer Research UK for Children & Young People is working towards a world where children and young people can live longer, better lives, free from the fear of cancer.  
  • Money raised through Cancer Research UK for Children & Young People will be used to fund research into cancers affecting children and young people (aged 0-24).  

For more information, please visit www.cruk.org/childrenandyoungpeople or follow us on Facebook at www.facebook.com/CRUKYoungPeople/.  

* Calculated by the Cancer Intelligence team at Cancer Research UK, August 2023. Deaths avoided for all cancers combined (ICD-10 C00-C97, D32-D33, D35.2-D35.4, D42-D43, D44.3-D44.5) were estimated separately for males and females aged 0-14 and 15-24 by comparing the observed annual number of cancer deaths in each 3-year rolling average period (1971-73 to 2018+19+21 inclusive) against the number of cancer deaths that would have occurred, had mortality rates remained at their 1971-1973 annual average levels. Deaths avoided for persons was estimated as the sum of deaths avoided for male and females.    

 

About Newcastle University 

Newcastle University, UK, is a thriving international community of more than 28,000 students from over 130 countries worldwide.

As a member of the Russell Group of research-intensive universities in the UK, Newcastle has a world-class reputation for research excellence in the fields of medicine, science and engineering, social sciences and the humanities.  

Its academics are sharply focused on responding to the major challenges facing society today. Research and teaching are world-leading in areas as diverse as health, culture, technology and the environment.  

Newcastle is committed to providing students with excellent, research-led teaching delivered by dedicated and passionate teachers.   

Newcastle University is ranked 110th in the QS World Ranking 2024 and joint 168 in the Times Higher Education World University Ranking 2024. 

Newcastle University is ranked fourth in the UK and joint 24 in the world for sustainable development in the Times Higher Education Impact Rankings 202

Notes to Editors:

About Children with Cancer UK: 

Children with Cancer UK is a leading children’s cancer charity dedicated to raising and investing funds into vital specialist research to save the lives of children and young people with cancer. Our mission is to improve survival rates and the quality of survival in young patients, and to find ways to prevent cancer in the future. Whilst working towards this, Children with Cancer UK funds support for children and their families as they navigate treatment. What began as a small memorial charity in 1988, has evolved into a major force raising more than £300 million and investing in over 200 pioneering research projects. 

Read other stories

Newsletter icon
Newsletter icon

Sign up to our e-newsletter today

Sign up to our e-newsletter and receive exclusive stories straight to your inbox. You will also find out about our latest childhood cancer research news along with updates on our fundraising events, charity news and opportunities to support us. Don’t miss out!

By signing up to this newsletter I agree to receive general and financial appeal emails from Children with Cancer UK